A laboratory-oriented guide to semaglutide identity, GLP-1 receptor research, selected clinical evidence, and the limits that matter when comparing studies.
Reviewed October 25, 2026. This page is a reading guide, not a systematic review or a substitute for a regulatory label.
Compound Evidence Library / Semaglutide
Semaglutide research identity and GLP-1 context
Semaglutide is a GLP-1 receptor agonist studied across cell, animal, and human research. These evidence levels answer different questions: receptor assays examine a defined biological response, models examine responses in an organism, and clinical trials estimate outcomes in a specified population using a defined study material and protocol.
What selected published studies show
The rows below are separate research questions. A shared compound name does not make every formulation, population, endpoint, or material equivalent.
| Study | Design and population | Interpretation boundary |
|---|---|---|
| STEP 1 Wilding et al., 2021 | Randomized trial in adults with overweight or obesity; weight and cardiometabolic outcomes were assessed over the registered follow-up. | Results describe the studied population, comparator, protocol, and product; they do not validate an unrelated research lot. |
| STEP 4 Rubino et al., 2021 | Withdrawal-design trial that compared continued treatment with a switch to placebo after a run-in period. | Withdrawal designs answer a maintenance question and should not be read as a general stability or permanence claim. |
| SURPASS-2 Frías et al., 2021 | Head-to-head comparison of tirzepatide and semaglutide in adults with type 2 diabetes, with glycemic endpoints. | Its diabetes population and comparator define the conclusion; it is not interchangeable with an obesity trial. |
| Regulatory label context FDA | U.S. prescribing information describes the regulated product, indications, warnings, and product-specific quality context. | A label is not a laboratory certificate for another material and does not replace lot-specific analytical documentation. |
Evidence limits, stability, and documentation
Before comparing studies, record the publication date, population, design, comparator, primary endpoint, missing-data approach, and stated limitations. Separate receptor-level hypotheses from clinical outcomes, and separate clinical pharmacology from the stability of a powder or solution.
A clinical publication or regulatory label does not establish identity, content, impurity profile, sterility, stability, or equivalence for an independently supplied research material. Those questions require material-specific methods and lot traceability.
For laboratory documentation, see how to read a peptide COA, purity versus content, and the study generalizability checklist.
Explore the semaglutide research articles
Choose the article that matches the question you are evaluating.
Comparator, population, endpoint, and study-design context.
How label language and formulation context should be separated from research materials.
How route and formulation questions change the evidence being compared.
How combination-program evidence is described without collapsing distinct compounds.
Read trial endpoints, comparators, and limitations in their own protocol.
Semaglutide research FAQs
What is semaglutide studied for in laboratory research?
Researchers study GLP-1 receptor signaling, pharmacology, formulation questions, and outcomes in defined experimental or clinical protocols. The question, model, and material determine what can be concluded.
Do STEP 1 and STEP 4 answer the same question?
No. STEP 1 evaluates outcomes in a specified trial population, while STEP 4 uses a withdrawal design to examine what happened after a run-in period and a treatment switch.
Does a clinical trial validate a research-use-only vial?
No. A trial studies its own defined material and protocol. A separate research material requires its own identity, content, impurity, stability, and traceability documentation.
Is a regulatory label the same as a COA?
No. A label describes a regulated product and its approved information. A COA is lot-specific analytical documentation and should be read with its methods and limitations.
How should I compare semaglutide studies?
Start with population, study design, comparator, endpoint, follow-up, analysis plan, and limitations. Then read the full paper and supplementary methods rather than comparing a headline number alone.
Primary sources and catalog context
Selected references:
- Wilding JP et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183.
- Rubino D et al. Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021. DOI: 10.1001/jama.2021.3224.
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2107519.
- FDA Wegovy prescribing information. Product-specific regulatory reference.
Semaglutide by Peptides Skin
PeptidesSkin.us and PeptidesSkin.com are the same Peptides Skin brand. This .us page provides research context; the .com link provides catalog information and does not establish equivalence to material used in the cited studies.
View product on PeptidesSkin.com →For laboratory research and educational purposes only. Not for human or veterinary use. This profile contains no dosing, preparation, or administration instructions.